ERBB3 and non-small cell lung carcinoma: These encouraging data supported the launch of the phase 3 HERTENALung02 trial (NCT05338970) which aims to compare the safety and efficacy of HER3-DXd versus chemotherapy in patients with advanced EGFR-mutated NSCLC who have failed third-generation EGFR TKIs but have not yet received chemotherapy [180].